Cochrane Review to Rank Best Early Interventions for Preeclampsia Prevention
A major Cochrane network meta-analysis protocol aims to compare and rank interventions for preeclampsia prevention before 17 weeks gestation.
Summary
Preeclampsia is a serious pregnancy complication linked to high blood pressure and organ damage, affecting both mother and baby. Researchers from Greek universities have registered a Cochrane network meta-analysis protocol designed to systematically compare and rank all available early interventions — such as aspirin, calcium, and other treatments — for preventing preeclampsia in high-risk pregnant women up to 16 weeks and 6 days gestation. Unlike standard pairwise meta-analyses, a network approach allows simultaneous comparison of multiple interventions, potentially revealing which options offer the greatest benefit with the least harm. This is a protocol registration, meaning the actual data collection and analysis are forthcoming. When completed, this review could provide the most comprehensive evidence-based ranking of preeclampsia prevention strategies to date, directly informing clinical guidelines and obstetric practice worldwide.
Detailed Summary
Preeclampsia remains one of the leading causes of maternal and perinatal morbidity and mortality worldwide, complicating an estimated 2–8% of pregnancies. Early identification and intervention in high-risk women — ideally before 17 weeks gestation — is now recognized as critical for meaningful prevention. Yet clinicians currently face an array of candidate interventions, including low-dose aspirin, calcium supplementation, vitamin D, progesterone, and others, without a unified comparative framework to guide decision-making.
This publication registers the protocol for a Cochrane systematic review using network meta-analysis (NMA) methodology. The study team, affiliated with the Aristotle University of Thessaloniki and the National and Kapodistrian University of Athens, plans to compare and rank the benefits and harms of interventions administered to pregnant women at increased preeclampsia risk who are no more than 16 weeks and 6 days pregnant.
Network meta-analysis is a powerful statistical method that enables simultaneous comparison of multiple interventions — even those never directly compared head-to-head in individual trials — by combining direct and indirect evidence across a network of studies. This approach is particularly valuable when many competing treatments exist but randomized trials have rarely compared them against each other directly.
Because this is a protocol rather than a completed review, no results are yet available. The final review is expected to produce a ranked hierarchy of interventions based on both efficacy (preeclampsia prevention) and safety outcomes, which could substantially reshape clinical guidelines in maternal-fetal medicine.
For clinicians managing high-risk pregnancies, this forthcoming evidence synthesis could provide long-awaited clarity on treatment prioritization. For health-conscious patients, it underscores that early pregnancy is a critical window for intervention. Caveats include that the review is not yet complete, and its conclusions will depend heavily on the quality and heterogeneity of included trials.
Key Findings
- This is a registered protocol for a Cochrane NMA comparing early preeclampsia prevention interventions — no results yet available.
- The review targets interventions given before 17 weeks gestation in women already identified as high-risk.
- Network meta-analysis will allow ranking of multiple treatments simultaneously, including those never directly compared.
- Outcomes will cover both benefits (preeclampsia prevention) and harms, providing a balanced clinical evidence base.
- Completion could reshape obstetric guidelines by identifying the most effective early intervention strategy.
Methodology
This is a protocol registration for a Cochrane systematic review using network meta-analysis. The NMA design enables indirect and direct comparisons across multiple interventions in high-risk pregnant women up to 16+6 weeks gestation. No data extraction or analysis has been conducted yet.
Study Limitations
This publication is a protocol only — no study results, data, or conclusions are available yet. The summary is based on the abstract alone, as the full text was not accessible. Final conclusions will depend on the number, quality, and heterogeneity of trials identified for inclusion.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.